PTC Receives Monetary Award From CFFT

PTC Therapeutics, (PTC), a biopharmaceutical company focused on the discovery, development and commercialization of small-molecule drugs targeting post-transcriptional control mechanisms, has announced that the company has been awarded $1.7 million from Cystic Fibrosis Foundation Therapeutics, (CFFT), the drug discovery and development affiliate of the Cystic Fibrosis Foundation. The award will be utilized to fund the development of PTC124 for the treatment of cystic fibrosis (CF) due to a nonsense mutation in the cystic fibrosis transmembrane regulator (CFTR) gene.

PR Newswire (http://www.prnewswire.com/cgi-bin/stories.pl?ACCT=104&STORY=/www/story/02-21-2005/0003065200&EDATE=)